ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near Boston, MA, USA:

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients (UNITY)

This research study involves Niraparib as a possible treatment for triple negative breast cancer....

Enrolling
Triple Negative Breast Cancer
Residual Disease
Drug: Niraparib
Radiation: Radiation Therapy

Phase 1

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 1 other location

This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer...

Active, not recruiting
Metastatic Breast Cancer
Triple Negative Breast Cancer
Biological: PVX-410
Drug: Pembrolizumab

Phase 1

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 2 other locations

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative b ...

Enrolling
Breast Cancer
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: Sacituzumab Govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 9 other locations

Status recently updated

with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer.The names of the study d...

Not yet enrolling
Enrolling
Breast Cancer
Breast Cancer Female
Drug: Carboplatin
Drug: Pembrolizumab

Phase 1, Phase 2

Filipa Lynce, MD

Boston, Massachusetts, United States

of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...

Enrolling
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Datopotamab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Boston, Massachusetts, United States and 46 other locations

inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer. This research study...

Active, not recruiting
Breast Cancer
Biological: Durvalumab
Biological: PVX-410

Phase 1

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 4 other locations

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Atezolizumab
Drug: Sacituzumab govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 8 other locations

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC).The Following drugs will be ...

Active, not recruiting
Inflammatory Breast Cancer (IBC)
Drug: Paclitaxel
Drug: Cyclophosphamide

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 3 other locations

This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative...

Enrolling
Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer
Breast Cancer
Drug: Paclitaxel
Drug: Onvansertib

Phase 1, Phase 2

Antonio Giordano, MD

Boston, Massachusetts, United States and 2 other locations

This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast ca...

Enrolling
HER2-negative Breast Cancer
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: Sacituzumab Govitecan

Phase 2

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 4 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems